Premium
Substitution Therapy with Recombinant Growth Hormone (Somatrem) in Adults with Growth Hormone Deficiency
Author(s) -
DEGERBLAD M.,
GRUNDITZ R.,
HALL K.,
SJÖBERG HE.,
SÄÄF M.,
THORÉN M.
Publication year - 1987
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1987.tb17156.x
Subject(s) - medicine , substitution therapy , growth hormone , growth hormone deficiency , endocrinology , hormone , recombinant dna , hormone therapy , biochemistry , chemistry , cancer , breast cancer , gene
. Degerhlad, M., Grunditz, R., Hail, K., Sjöberg, H. E., Sääf, M. and Thorén, M. (Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden). Substitution therapy with recombinant growth hormone (somatrem) in adults with growth hormone deficiency. Acta Paediatr Scand [Suppl] 337:170, 1987. The effects of a 12‐week period of substitution therapy with somatrem have been investigated in six adults with confirmed hGH deficiency. Five of the six patients experienced a subjective improvement, mentally and physically, but these improvements were not demonstrated when the patients were assessed objectively. No side‐effects were reported. Serum procollagen III peptide increased in all patients and serum IGF‐1 increased in five of the six patients.